scholarly journals ‘Cool’ and ‘Hot’ executive functions in suicide attempters with major depressive disorder

2018 ◽  
Vol 235 ◽  
pp. 332-340 ◽  
Author(s):  
Ming-Chou Ho ◽  
Yi-Chieh Hsu ◽  
Mong-Liang Lu ◽  
Michael Gossop ◽  
Vincent Chin-Hung Chen
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nicolas Salvetat ◽  
Fabrice Chimienti ◽  
Christopher Cayzac ◽  
Benjamin Dubuc ◽  
Francisco Checa-Robles ◽  
...  

AbstractMental health issues, including major depressive disorder, which can lead to suicidal behavior, are considered by the World Health Organization as a major threat to global health. Alterations in neurotransmitter signaling, e.g., serotonin and glutamate, or inflammatory response have been linked to both MDD and suicide. Phosphodiesterase 8A (PDE8A) gene expression is significantly decreased in the temporal cortex of major depressive disorder (MDD) patients. PDE8A specifically hydrolyzes adenosine 3′,5′-cyclic monophosphate (cAMP), which is a key second messenger involved in inflammation, cognition, and chronic antidepressant treatment. Moreover, alterations of RNA editing in PDE8A mRNA has been described in the brain of depressed suicide decedents. Here, we investigated PDE8A A-to-I RNA editing-related modifications in whole blood of depressed patients and suicide attempters compared to age-matched and sex-matched healthy controls. We report significant alterations of RNA editing of PDE8A in the blood of depressed patients and suicide attempters with major depression, for which the suicide attempt took place during the last month before sample collection. The reported RNA editing modifications in whole blood were similar to the changes observed in the brain of suicide decedents. Furthermore, analysis and combinations of different edited isoforms allowed us to discriminate between suicide attempters and control groups. Altogether, our results identify PDE8A as an immune response-related marker whose RNA editing modifications translate from brain to blood, suggesting that monitoring RNA editing in PDE8A in blood samples could help to evaluate depressive state and suicide risk.


2013 ◽  
Vol 74 (4) ◽  
pp. 287-295 ◽  
Author(s):  
Jeffrey M. Miller ◽  
Natalie Hesselgrave ◽  
R. Todd Ogden ◽  
Gregory M. Sullivan ◽  
Maria A. Oquendo ◽  
...  

2004 ◽  
Vol 65 (5) ◽  
pp. 690-695 ◽  
Author(s):  
Bernard Astruc ◽  
Stephane Torres ◽  
Fabrice Jollant ◽  
Sophie Jean-Baptiste ◽  
Didier Castelnau ◽  
...  

2010 ◽  
Vol 177 (3) ◽  
pp. 323-329 ◽  
Author(s):  
Ixchel Herrera-Guzmán ◽  
Jorge E. Herrera-Abarca ◽  
Esteve Gudayol-Ferré ◽  
Daniel Herrera-Guzmán ◽  
Lizbeth Gómez-Carbajal ◽  
...  

2011 ◽  
Vol 187 (1-2) ◽  
pp. 135-139 ◽  
Author(s):  
Ludvig Hallberg ◽  
Åsa Westrin ◽  
Anders Isaksson ◽  
Shorena Janelidze ◽  
Lil Träskman-Bendz ◽  
...  

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Miquel Roca ◽  
Antonio Riera-López del Amo ◽  
Pau Riera-Serra ◽  
Mª. Angeles Pérez-Ara ◽  
Adoración Castro ◽  
...  

2018 ◽  
Vol 29 (3) ◽  
pp. 332-339 ◽  
Author(s):  
Merve Onat ◽  
Neslihan İnal Emiroğlu ◽  
Burak Baykara ◽  
Ayşegül Özerdem ◽  
Gonca Özyurt ◽  
...  

2021 ◽  
pp. 1-11
Author(s):  
Olivia Bauer ◽  
Vladimir M. Milenkovic ◽  
Sven Hilbert ◽  
Nina Sarubin ◽  
Johannes Weigl ◽  
...  

<b><i>Introduction:</i></b> Inflammatory processes play an important role in the pathophysiology of major depressive disorder (MDD), but their relevance for specific symptoms such as neurocognitive impairment is rarely investigated. <b><i>Methods:</i></b> In this observational study, we investigated the changes of leukocyte chemokine (C-C motif) receptor 5 (CCR5) and ligand 5 (CCL5) mRNA levels and inflammatory cytokines in 60 MDD patients before (PRE) and after 5 weeks (W5) of antidepressive treatment in relation to therapy response and alterations in cognitive functions by means of the Cambridge Neuropsychological Test Automated Battery (CANTAB). We hypothesized that elevated CCR5 and CCL5 levels in depressed patients would decrease upon treatment and could differ with regard to cognitive impairment associated with MDD. <b><i>Results:</i></b> Both CCR5 and CCL5 levels were significantly decreased in the responder group compared to nonresponders even before treatment. The cytokine IL-6 as a marker of inflammation in depression did not show a difference before treatment in future responders versus nonresponders, but decreased significantly upon antidepressive therapy. Regarding neurocognitive impairment in MDD patients, an increased misperception of the emotion “anger” after 5 weeks of treatment proved to be associated with a more pronounced change in CCR5, and the perception of the emotion “disgust” became faster along with a stronger decrease in CCL5 over the same time. Executive functions typically impaired in MDD patients were not markedly associated with alterations in CCR5/CCL5. <b><i>Discussion:</i></b> CCR5 and CCL5 are important in the targeting of immune cells by HIV. This is the first study providing valuable hints that both CCR5 and CCL5 might also serve as markers of therapy response prediction in MDD. Regarding neurocognitive impairment in depression, CCR5 and CCL5 did not reveal characteristic changes upon MDD treatment such as executive functions, which are probably delayed. However, changes of emotional perception appear to be an earlier responding feature.


Sign in / Sign up

Export Citation Format

Share Document